Democrats’ Pricing Legislation Insufficient; PhRMA’s Criticism of Policies Unwarranted

November 10, 2021

Attempts to reduce drug costs via policy changes are insufficient. Despite the relatively small scale of new legislation, including allowing for Medicare to negotiate the prices of a small number of drugs with pharma, PhRMA has been vocal in its disapproval. Still, the relatively small policy changes could signal future pharma upheaval.

“Meanwhile, industry group PhRMA, which successfully flooded Capitol Hill with 20 lobbyists for every senator, is once again disingenuously crying foul. This is typical of PhRMA, which often makes a big, public stink about already-limited bills while watering them down further behind closed doors.” Read more here.

(Source: Zachary Brennan, Endpoints News, 11/10/21)

Share This Story!